Printed From BioPortfolio.com
CFDA Plans to Double Drug Review Staff: From 800 to 1,600
05:14 EST 12 Jan 2018 | ChinaBio Today
According to an article in BioCentury, the CFDA plans to double its drug application reviewers from 800 presently to 1,600 by 2020. In 2015, the CFDA employed just 170 reviewers, meaning the agency will increase its reviewing staff by almost 10-fold over a six-year period. The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation, who was speaking at the WuXi Global Forum in
Share this with colleagues:
Original Article: CFDA Plans to Double Drug Review Staff: From 800 to 1,600
